BMS is funding the Houston build under a five-year, $40 billion pledge covering US research and development, technology and manufacturing.1 The commitment lands amid a broader run of reshoring and capacity announcements from large biopharmaceutical manufacturers weighing supply chain resilience and proximity to US commercial markets against tariff policy and the cost edge of overseas production. Pharmaceutical Commerce has followed that shift through the industry's evolving domestic manufacturing push and the separate question of whether reshored capacity is landing where the supply chain needs it most . How Does the Project Fit Into Pharma's Broader Reshoring Push? "1 She added that the investment "strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands." BMS expects construction and build-out to continue through 2030.